Form 4: Neogenomics Director Elizabeth Floegel Reports Stock Transactions

Director Elizabeth Floegel reported the release of restricted stock units and subsequent ownership of common stock in Neogenomics.

Summary

• On August 10, 2024, Elizabeth Floegel, a director of Neogenomics Inc., reported transactions involving the company's stock.
• The transactions involved the release of 11,336 restricted stock units, which converted into 11,336 shares of common stock.
• Following the transaction, Floegel directly owns 11,336 shares of Neogenomics common stock.
• Floegel also holds stock options to purchase 8,353 shares at $14.82, expiring on August 10, 2033, and 8,672 shares at $13.71, expiring on June 1, 2034.
• Additionally, Floegel holds 12,254 restricted stock units.

Sentiment

Score: 5

Explanation: This is a neutral document, simply reporting stock transactions. It doesn't inherently indicate positive or negative sentiment about the company's performance.

Industry Context

This filing is a routine disclosure of stock transactions by a company insider, which is common in publicly traded companies. It provides transparency to investors regarding the actions of company leadership.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies, ensuring transparency in insider trading.
• The details provided are consistent with SEC requirements for reporting changes in beneficial ownership.
• Comparable companies like Exact Sciences (EXAS) and Guardant Health (GH) also have directors and officers who regularly file Form 4s to report their stock transactions.

Stakeholder Impact

• The filing provides transparency to shareholders regarding insider transactions.
• It can influence investor sentiment depending on the perceived reasons behind the transactions.

Key Dates